Geninca // EU Project

Project description:

GENINCA will address two tumour entities, for which we have good access to pre-malignant lesions and in which genomic instability is a common feature, namely colorectal and liver cancer. Colorectal cancers amount to 13.2% of all incident cases of cancer, the second most common form of cancer, surpassed only by lung cancer (13.3%). Liver cancer accounts for about 2% of total cancers, however, the most common liver cancer, i.e. hepatocellular carcinoma (HCC), is among the most lethal forms of cancer, and its incidence in Europe has been steadily rising over the last few decades. GENINCA represents a collaborative study of 8 academic and 3 industrial partners from 5 European countries. GENINCA will focus on exploring pre-cancerous and cancer lesions of the two aforementioned tumour entities and their respective microenvironments. The recent identification of human colon-cancer initiating cells by one of our academic consortium members paves the way for completely new strategies for studying mechanisms of tumorigenesis, thus, a particular focus of this grant proposal will be the detailed characterisation of these cancer initiating stem cells. At present, it is still a matter of debate which genomic changes are already present in precursor lesions and whether these lesions already show genetic instability. We will therefore address the occurrence of genomic instability and explore their underlying mechanisms especially in pre-cancerous and early cancer lesions. This will be greatly facilitated by in vivo endomicroscopy approaches, sophisticated animal models and large-scale genomic and proteomic analyses. Furthermore, we will conduct an in-depth analysis of the corresponding microenvironment. As this represents a translational research effort, we expect to identify markers for novel therapeutic and/or preventative strategies, as well as facilitate improved tumour diagnosis, prognosis and monitoring.


Quick overview:

Programme: FP7-HEALTH
Project References: 202230
Coordinator: Medical University of Graz, Austria
Status: Completed
Start: 01.01.2008
End: 30.06.2011
Total Cost: EUR 4,033,238.15
EU contribution: EUR 2,995,569


biolution contribution:

Proposal preparation: Content, Administration
Grant preparation: Contract development, Budget, Consortium Agreement
Implementation: Project Management, Dissemination

Partners / Collaborations

biolution GmbH, AT
Medical University of Graz, AT
Oridis Biomed R&D GmbH, AT
INSERM U872, Cordeliers Research Center, FR
Mosaiques diagnostics GmbH, DE
University Hospital of Erlangen, DE
University Medical Center Hamburg-Eppendorf, DE
Ulm University, DE
IFOM – FIRC Insitute of Molecular Oncology, IT
Istituto Superiore di Sanità, IT
The Cancellor, Masters and Scholars of the University of Oxford, UK


Cancer Communication Consulting EU Projects FP7 Project Management

Related items: